logo
  

Medtronic ADAPT Study Results Of MiniMed 780G Insulin Pump Positive

Medtronic plc (MDT) on Thursday reported results from the ADAPT study of its MiniMed 780G insulin pump, that continuously monitors and automatically adjusts insulin dosages round the clock.

The ADAPT study evaluated the performance of MiniMed 780G system versus standard of care in 82 individuals with type 1 diabetes, who are not currently meeting glycemic targets.

At study initiation, half of the participants moved on to use MiniMed 780G system, while the other half continued with standard of care to control their glycemic levels.

Results from the study showed improvement in glycemic targets for those that transitioned to the MiniMed 780G system with a significant and sustained 1.4% HbA1C reduction at six months. Those using the Medtronic system also saw a 27.6% absolute increase in Time in Range (6.6 more hours/day in target range) compared to those on standard of care without increased in time in hypoglycemia. This improvement was even greater overnight when the algorithm was in full control, Medtronic said.

The results were published in The Lancet Diabetes & Endocrinology.

The MiniMed 780G system, currently under review by the Food and Drug Administration, is available in more than 60 countries across the globe.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton. Elon Musk, who recently took Twitter Inc. private in a $44-billion deal, accused Apple Inc. of threatening to block the social media platform from its app store without giving the reason. In a series of tweets on Monday, the Tesla founder and CEO also said the tech giant had stopped advertising on Twitter, and that it was pressuring the firm over content moderation demands.
Follow RTT